Tag Archives: Emerging Companies

Members of Congress Agree: Reg A+ Rules Need National Standard

Biotech IPOs Infographic

We’ve written before about the importance of implementing Title IV of the JOBS Act (commonly referred to as the “Reg A+” provision) in a way that will best encourage biotech capital formation. BIO President and CEO Jim Greenwood also discussed the issue in an op-ed at Forbes last week. At issue is whether the SEC will set a national standard for the review of Reg A+ offerings or instead subject companies to the labyrinth that Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , ,

NCATS SBIR Announces Funding For Biotechs and Small Business Technology Development

lab_tech

The NIH National Center for Advancing Translational Sciences (NCATS) is seeking qualified applicants for its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. NCATS, which offers $17.6 million annually through these programs, has issued a call for applications for two funding opportunities: Contract funding to support small businesses and venture-backed technology development, due Nov. 5, 2014. Investigator-initiated grant funding,due Dec. 5, 2014. NCATS’ SBIR and STTR programs are engines of innovation Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Roadblocks and Red Tape Block Search for Cures

scientist-eyedropper

Since its passage more than two years ago, the JOBS Act has spurred more than 110 biotech IPOs. And now the SEC is in the process of finalizing another important piece of the law that could further encourage biotech capital formation. The JOBS Act directs the SEC to raise the offering ceiling under Regulation A – a securities law exemption that allows companies to raise public capital with a reduced reporting burden – from $5 Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Biotech CEOs Speak Out on JOBS Act Success

Biotech IPOs Infographic

Enacted in April 2012, the Jumpstart Our Business Startups (JOBS) Act makes the pathway to capital formation more attainable for small biotechnology companies, clearing the way for American innovation and ingenuity by removing bureaucratic hurdles and red tape to speed cures and medical breakthroughs to patients. The JOBS Act reached a major milestone last week, with the 100th company going public under its provisions. On October 7th at the 13th Annual BIO Investor Forum, we Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Biotech Stocks: Perspective in a Bull Market

biotech companies

Investors are increasingly interested in biotechnology based on scientific breakthroughs, an improved regulatory environment, strong earnings growth from large companies, and a more mature industry. Recent advancements in biotechnology are revolutionizing treatments and cures for many illnesses, creating new value for the healthcare system. In 2013, our understanding of how therapeutics can be used to harness the immune system to destroy cancer cells exploded with many companies reporting solid data in human testing. In 2014, Read More >

Inside BIO Industry Analysis  |  1 Comment  |  Email This Post
Tags: , , , , , , ,